Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients

Shan Yu,1 Yan Wang,1 Xi Cheng,2 Minzhi Lv,3 Yuehong Cui,1 Wei Li,1 Yiyi Yu,1 Qian Li,1 Tianshu Liu1,4 1Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University...

Full description

Bibliographic Details
Main Authors:	Yu S, Wang Y, Cheng X, Lv M, Cui Y, Li W, Yu Y, Li Q, Liu T
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-10-01
Series:	Cancer Management and Research
Subjects:	gastric cancer gastrectomy adjuvant chemotherapy capecitabine oxaliplatin s-1 xelox
Online Access:	https://www.dovepress.com/prognosis-of-adjuvant-sox-vs-xelox-chemotherapy-for-gastric-cancer-aft-peer-reviewed-article-CMAR

Similar Items

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
by: Jianhong Peng, et al.
Published: (2019-10-01)

Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study
by: Tsunekazu Mizushima, et al.
Published: (2019-09-01)

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
by: Yuanyuan Yu, et al.
Published: (2021-05-01)

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
by: Kyaw Z. Thein, et al.
Published: (2021-12-01)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
by: Mohammad Ali Mashhadi, et al.
Published: (2016-10-01)

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)
by: Yizhang Chen, et al.
Published: (2023-10-01)

Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
by: Tsutomu Namikawa, et al.
Published: (2018-02-01)

Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer
by: Xiao-Yin Zhao, et al.
Published: (2022-10-01)

Computational Tactics for Precision Cancer Network Biology
by: Heewon Park, et al.
Published: (2022-11-01)

A Randomised Controlled Phase II Trial of the Combination of XELOX with Thalidomide for the First-line Treatment of Metastatic Colorectal Cancer
by: Jing Lv, et al.
Published: (2012-06-01)

Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: A retrospective analysis from a medical center
by: Yung-Chia Kuo, et al.
Published: (2014-06-01)

ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER?
by: Nelson Adami ANDREOLLO, et al.
Published: (2019-12-01)

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
by: Guoxiu Wang, et al.
Published: (2018-05-01)

Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
by: Kabsoo Shin, et al.
Published: (2019-12-01)

The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer
by: Jun-Bing Chen, et al.
Published: (2022-12-01)

Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S‐1 chemotherapy after gastrectomy: A multicenter, open‐label, single‐arm, prospective phase II study (OGSG1108)
by: Hiroshi Imamura, et al.
Published: (2021-11-01)

S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysis
by: S.M.Zeeshan Qadar, et al.
Published: (2024-01-01)

Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial
by: Xinxin Wang, et al.
Published: (2024-04-01)

Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
by: Jia X, et al.
Published: (2023-03-01)

Adjuvant Chemotherapy Might Be Recommended to Patients With Positive Margin After Gastrectomy: A 20-Year Retrospective Analysis in a Single Center
by: Xiaojie Zhang, et al.
Published: (2022-02-01)

Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer
by: Yoichiro Yoshida, et al.
Published: (2014-02-01)

The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial
by: Qun Zhao, et al.
Published: (2020-08-01)

Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
by: Jianming Xu, et al.
Published: (2021-01-01)

Adjuvant Chemoradiotherapy for Gastric Cancer: Efficacy and Cost-Effectiveness Analysis
by: Mengxi Zhang, et al.
Published: (2019-12-01)

A meta-analysis of robotic gastrectomy versus open gastrectomy in gastric cancer treatment
by: Lei Chen, et al.
Published: (2022-02-01)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
by: Akihiko Hatano, et al.
Published: (2023-11-01)

Laparoscopic gastrectomy for gastric carcinoma with neoadjuvant chemotherapy
by: Shimpei Furuta, et al.
Published: (2017-11-01)

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
by: Haiping Jiang, et al.
Published: (2020-08-01)

Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature
by: You Zou, et al.
Published: (2021-11-01)

Cardiotoxicity induced by capecitabine and oxaliplatin in gastric cancer treatment: a rare case of cardiac arrest and cardiogenic shock
by: Muhammad Umer Riaz Gondal, et al.
Published: (2024-03-01)

Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer
by: Wang G, et al.
Published: (2023-07-01)

First reported case of ANCA-associated vasculitis induced by oxaliplatin, capecitabine, and trastuzumab
by: Bengang Huo, et al.
Published: (2023-12-01)

Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery
by: Sha Li, et al.
Published: (2024-04-01)

Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
by: Anchuan Li, et al.
Published: (2022-07-01)

Short and Long-Term Surgical Outcomes of Laparoscopic Total Gastrectomy Compared with Open Total Gastrectomy in Gastric Cancer Patients
by: Sang Soo Eom, et al.
Published: (2022-12-01)

Analysis of capecitabine plus oxaliplatin (xelox) combination in the management of metastatic colorectal cancer compare with fluorouracil and oxaliplatin combination (folfox)
by: Isnatin Miladiyah
Published: (2016-12-01)

Robotic versus laparoscopic gastrectomy with D2 lymph node dissection for advanced gastric cancer: a propensity score-matched analysis
by: Li Z, et al.
Published: (2018-04-01)

Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
by: Renata Ferrarotto, et al.
Published: (2013-09-01)

XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)
by: Xiao‐Dong Zhu, et al.
Published: (2022-04-01)

Laparoscopic vs. Open Gastrectomy for Locally Advanced Gastric Cancer: A Propensity Score-Matched Retrospective Case-Control Study
by: Stefano Caruso, et al.
Published: (2022-03-01)